Company Description
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally.
It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders.
Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; and LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder.
It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International.
The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products.
Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.
| Country | Ireland |
| Founded | 1987 |
| IPO Date | Jul 16, 1991 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 2,100 |
| CEO | Richard Pops |
Contact Details
Address: Connaught House, 1 Burlington Road Dublin, D04 C5Y6 Ireland | |
| Phone | 353 1 772 8000 |
| Website | alkermes.com |
Stock Details
| Ticker Symbol | ALKS |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001520262 |
| CUSIP Number | G01767105 |
| ISIN Number | IE00B56GVS15 |
| Employer ID | 98-1007018 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Richard F. Pops | Chairman and Chief Executive Officer |
| Blair C. Jackson | Interim Principal Financial Officer, Executive Vice President, Chief Risk Officer and Chief Operating Officer |
| David Joseph Gaffin J.D. | Executive Vice President, Chief Legal Officer, Chief Compliance Officer and Secretary |
| Iain Michael Brown | Senior Vice President and Chief Financial Officer |
| Dr. Craig C. Hopkinson M.D. | Executive Vice President of Research and Development and Chief Medical Officer |
| Dr. Floyd E. Bloom M.D. | Founder |
| Samuel J. Parisi | Interim Principal Accounting Officer and Vice President of Finance |
| Thomas Harvey | Chief Information Officer and Senior Vice President of IT |
| Sandra Coombs | Senior Vice President of Corporate Affairs and Investor Relations |
| Stephen Schiavo | Senior Vice President and Chief Human Resources Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 19, 2024 | 8-K | Current Report |
| Dec 9, 2024 | 144 | Filing |
| Dec 9, 2024 | 144 | Filing |
| Dec 5, 2024 | 144 | Filing |
| Dec 4, 2024 | 144 | Filing |
| Dec 2, 2024 | 8-K | Current Report |
| Nov 27, 2024 | 144 | Filing |
| Nov 14, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Nov 12, 2024 | 144 | Filing |
| Nov 12, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |